US Stock MarketDetailed Quotes
ACXP Acurx Pharmaceuticals
- 2.110
- -0.030-1.40%
Close Aug 2 16:00 ET
- 2.140
- +0.030+1.42%
Post 20:01 ET
33.43MMarket Cap-1788P/E (TTM)
2.160High1.900Low94.62KVolume2.080Open2.140Pre Close194.10KTurnover0.70%Turnover RatioLossP/E (Static)15.84MShares8.82052wk High5.57P/B28.36MFloat Cap1.17052wk Low--Dividend TTM13.44MShs Float8.820Historical High--Div YieldTTM12.15%Amplitude1.170Historical Low2.051Avg Price1Lot Size
Acurx Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | 50.81%4.38M | 20.55%14.58M | 56.86%5.11M | -12.05%3.11M | 31.47%3.45M | 8.72%2.9M | -5.63%12.09M | 24.11%3.26M | -23.71%3.54M | -35.62%2.62M |
| Selling and administrative expenses | 49.57%2.82M | 16.29%8.53M | 73.53%3.17M | -9.46%1.77M | 0.00%1.71M | 1.95%1.89M | -31.95%7.34M | -4.34%1.83M | -44.51%1.95M | -57.02%1.71M |
| -General and administrative expense | 49.57%2.82M | 16.29%8.53M | 73.53%3.17M | -9.46%1.77M | 0.00%1.71M | 1.95%1.89M | -31.95%7.34M | -4.34%1.83M | -44.51%1.95M | -57.02%1.71M |
| Research and development costs | 53.12%1.56M | 27.12%6.04M | 35.60%1.94M | -15.21%1.35M | 90.46%1.74M | 24.02%1.02M | 134.18%4.75M | 100.03%1.43M | 41.18%1.59M | 858.93%911.69K |
| Operating profit | -50.81%-4.38M | -20.55%-14.58M | -56.86%-5.11M | 12.05%-3.11M | -31.47%-3.45M | -8.72%-2.9M | 5.63%-12.09M | -24.11%-3.26M | 23.71%-3.54M | 35.62%-2.62M |
| Net non-operating interest income expense | ||||||||||
| Other net income (expense) | ||||||||||
| Income before tax | -50.81%-4.38M | -20.55%-14.58M | -56.86%-5.11M | 12.05%-3.11M | -31.47%-3.45M | -8.72%-2.9M | 5.14%-12.09M | -24.11%-3.26M | 23.71%-3.54M | 34.55%-2.62M |
| Income tax | ||||||||||
| Net income | -50.81%-4.38M | -20.55%-14.58M | -56.86%-5.11M | 12.05%-3.11M | -31.47%-3.45M | -8.72%-2.9M | 5.14%-12.09M | -24.11%-3.26M | 23.71%-3.54M | 34.55%-2.62M |
| Net income continuous Operations | -50.81%-4.38M | -20.55%-14.58M | -56.86%-5.11M | 12.05%-3.11M | -31.47%-3.45M | -8.72%-2.9M | 5.14%-12.09M | -24.11%-3.26M | 23.71%-3.54M | 34.55%-2.62M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -50.81%-4.38M | -20.55%-14.58M | -56.86%-5.11M | 12.05%-3.11M | -31.47%-3.45M | -8.72%-2.9M | 5.14%-12.09M | -24.11%-3.26M | 23.71%-3.54M | 34.55%-2.62M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -50.81%-4.38M | -20.55%-14.58M | -56.86%-5.11M | 12.05%-3.11M | -31.47%-3.45M | -8.72%-2.9M | 5.14%-12.09M | -24.11%-3.26M | 23.71%-3.54M | 34.55%-2.62M |
| Basic earnings per share | -12.00%-0.28 | -2.68%-1.15 | -35.71%-0.38 | 25.00%-0.24 | -7.69%-0.28 | 3.85%-0.25 | 24.83%-1.12 | -27.27%-0.28 | 30.43%-0.32 | 54.39%-0.26 |
| Diluted earnings per share | -12.00%-0.28 | -2.68%-1.15 | -35.71%-0.38 | 25.00%-0.24 | -7.69%-0.28 | 3.85%-0.25 | 24.83%-1.12 | -27.27%-0.28 | 30.43%-0.32 | 54.39%-0.26 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg